Read by QxMD icon Read

Luminal a breast cancer liu

Wenjuan Ma, Yumei Zhao, Yu Ji, Xinpeng Guo, Xiqi Jian, Peifang Liu, Shandong Wu
RATIONALE AND OBJECTIVES: This study aimed to investigate whether quantitative radiomic features extracted from digital mammogram images are associated with molecular subtypes of breast cancer. MATERIALS AND METHODS: In this institutional review board-approved retrospective study, we collected 331 Chinese women who were diagnosed with invasive breast cancer in 2015. This cohort included 29 triple-negative, 45 human epidermal growth factor receptor 2 (HER2)-enriched, 36 luminal A, and 221 luminal B lesions...
March 8, 2018: Academic Radiology
Ye Liu, Mei Yuan, Chao Wu, Tianhui Zhu, Wei Sun
Breast cancer is the most common invasive cancer in women worldwide, and can be subdivided into Luminal A, Luminal B, Her2, and Basal subtype (the PAM50 subtyping system). The lmo2 gene was traditionally recognized as a proto-oncogene in hematopoietic system but its functions in breast cancers remained largely unclear. Based on the Cancer Genome Atlas (TCGA) breast cancer dataset, herein we found that the significantly LMO2-correlated genes in normal or malignant samples were enriched in rather divergent cellular pathways, suggesting the function complexity of LMO2 in breast tissues...
February 6, 2018: Oncotarget
Rui Chen, Yin Ye, Chengcheng Yang, Yang Peng, Beige Zong, Fanli Qu, Zhenrong Tang, Yihua Wang, Xinliang Su, Hongyuan Li, Guanglun Yang, Shengchun Liu
PURPOSE: To assess the predictive role of pretreatment ki67 and Ki67 changes in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular subtypes. METHODS: 1010 BC patients who had undergone anthracycline and taxane-based NAC from January 2012 to July 2017 were retrospectively analyzed. Clinical and pathological parameters of the patients were retrieved and the predictive factors for NAC response were evaluated. RESULTS: 705 patients showed clinical response (cRes), and 131 patients acquired pathologic complete response (pCR)...
February 26, 2018: Breast Cancer Research and Treatment
Praveena S Thiagarajan, Maksim Sinyuk, Soumya M Turaga, Erin E Mulkearns-Hubert, James S Hale, Vinay Rao, Abeba Demelash, Caner Saygin, Arnab China, Tyler J Alban, Masahiro Hitomi, Luke A Torre-Healy, Alvaro G Alvarado, Awad Jarrar, Andrew Wiechert, Valery Adorno-Cruz, Paul L Fox, Benjamin C Calhoun, Jun-Lin Guan, Huiping Liu, Ofer Reizes, Justin D Lathia
Tumors adapt their phenotypes during growth and in response to therapies through dynamic changes in cellular processes. Connexin proteins enable such dynamic changes during development, and their dysregulation leads to disease states. The gap junction communication channels formed by connexins have been reported to exhibit tumor-suppressive functions, including in triple-negative breast cancer (TNBC). However, we find that connexin 26 (Cx26) is elevated in self-renewing cancer stem cells (CSCs) and is necessary and sufficient for their maintenance...
February 8, 2018: Nature Communications
Q Liu, H Y Xiang, J M Ye, L Xu, H Zhang, S Zhang, X N Duan, Y H Liu
Objective: To study the clinicopathological characteristics and the prognostic determinants of the invasive lobular carcinoma breast cancer. Methods: This was a retrospective single-center study of invasive lobular breast cancer cases diagnosed from January 2008 to December 2014 at Peking University First Hospital Breast Disease Center. The study enrolled 68 invasive lobular breast cancer patients, which represented 3.64% (68/1 870) of total invasive breast cancer. The median age of all selected patients was 46 years ranging from 36 to 83 years...
February 1, 2018: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Shunheng Zhou, Lihong Wang, Qian Yang, Haizhou Liu, Qianqian Meng, Leiming Jiang, Shuyuan Wang, Wei Jiang
BACKGROUND: Breast cancer is one of the most common solid tumors in women involving multiple subtypes. However, the mechanism for subtypes of breast cancer is still complicated and unclear. Recently, several studies indicated that long non-coding RNAs (lncRNAs) could act as sponges to compete miRNAs with mRNAs, participating in various biological processes. METHODS: We concentrated on the competing interactions between lncRNAs and mRNAs in four subtypes of breast cancer (basal-like, HER2+, luminal A and luminal B), and analyzed the impacts of competing endogenous RNAs (ceRNAs) on each subtype systematically...
February 1, 2018: Breast Cancer Research and Treatment
Fengxia Qin, Huikun Zhang, Yong Huang, Limin Yang, Feng Yu, Xiaoli Liu, Li Fu, Feng Gu, Yongjie Ma
Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate to guide patient selection for personalized cancer treatments. DPD (dihydropyrimidine dehydrogenase, encoded by DPYD gene) is the initial and rate-limiting enzyme of metabolic pathway of fluoropyrimidines, and fluoropyrimidines are common used drug therapies for breast cancer. Previous studies on DPYD polymorphism were mainly focused on its association with fluoropyrimidines toxicity. In our present study, 5 DPYD single nucleotide polymorphisms status was detected from tumor tissues of 331 invasive breast cancer patients using standard techniques...
December 19, 2017: Oncotarget
Fangxuan Li, Lijuan Wei, Shixia Li, Juntian Liu
Purpose: Indoleamine-2,3-dioxygenase (IDO) and Interleukin-6 (IL-6) contribute to poor therapeutic effects, tumor relapse and aggressive tumor growth. IDO and IL-6 incorporate a positive feedback signal loop to maintain IDO and IL-6 constitutive expression and facilitate tumor progression. Results: IDO expression was associated with IL-6 expression and plasma IL-6 level (P<0.05). Concentrating on clinicopathological features prior neoadjuvant chemotherapy, both IDO expression and plasma IL-6 level were associated with clinical T stage and N stage (P<0...
December 8, 2017: Oncotarget
Lan Mu, Yuxiang Liu, Meng Xiao, Weise Liu, Miao Liu, Xin Wang
The role of triple-negative breast cancer (TNBC) in breast-conserving treatment is controversial. The present study aimed at evaluating the prognosis of patients with TNBC following breast-conserving treatment (BCT) within 5 years. The present study investigated a cohort of 757 patients with early stage breast cancer, diagnosed and treated with BCT between January 2002 and March 2010 at Tianjin Medical University Cancer Institute and Hospital. The patients were divided into three groups according to receptor expression: Estrogen receptor (ER) or progesterone receptor (PR)-positive; epidermal growth factor receptor 2 (HER2)-enriched: ER and PR negative but HER2-positive; TNBC: ER, PR and HER2 receptor-negative...
December 2017: Oncology Letters
Jessica Young, Tsutomu Kawaguchi, Li Yan, Qianya Qi, Song Liu, Kazuaki Takabe
MicroRNAs (miRNAs) have emerged as one of the crucial regulators of cancer progression. Some miRNAs are reported to be related to the response of breast cancer to tamoxifen (TAM). In this study, we investigated whether the levels of TAM response-related miRNAs translate to patient survival. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets were used and Gene Set Enrichment Analysis (GSEA) was performed. Four TAM response-related miRNAs, miR-221, miR-222, miR-342, and miR-451, were identified by literature search...
November 21, 2017: Oncotarget
Jian-Ying Zhou, Lijun Chen, Bai Zhang, Yuan Tian, Tao Liu, Stefani N Thomas, Li Chen, Michael Schnaubelt, Emily Boja, Tara Hiltke, Christopher R Kinsinger, Henry Rodriguez, Sherri R Davies, Shunqiang Li, Jacqueline E Snider, Petra Erdmann-Gilmore, David L Tabb, R Reid Townsend, Matthew J Ellis, Karin D Rodland, Richard D Smith, Steven A Carr, Zhen Zhang, Daniel W Chan, Hui Zhang
Clinical proteomics requires large-scale analysis of human specimens to achieve statistical significance. We evaluated the long-term reproducibility of an iTRAQ (isobaric tags for relative and absolute quantification)-based quantitative proteomics strategy using one channel for reference across all samples in different iTRAQ sets. A total of 148 liquid chromatography tandem mass spectrometric (LC-MS/MS) analyses were completed, generating six 2D LC-MS/MS data sets for human-in-mouse breast cancer xenograft tissues representative of basal and luminal subtypes...
December 1, 2017: Journal of Proteome Research
Ke-Wen He, Ju-Jie Sun, Zai-Bo Liu, Pei-Ying Zhuo, Qing-Hua Ma, Zhao-Yun Liu, Zhi-Yong Yu
Lymphatic vessel invasion (LVI) is promising in determining prognosis and treatment strategies, but the application of LVI as a histopathological criterion in breast cancer patients especially those of different subgroups is controversial. This research aims to evaluate the prognostic value of LVI assessed by D2-40 not only in patients with early invasive breast cancer but also in lymph node-negative, lymph node-positive, luminal A-like, luminal B-like, HER2-enriched, and triple-negative subgroups.The study cohort included 255 patients with a median follow-up of 101 months...
November 2017: Medicine (Baltimore)
Tingting Zuo, Hongmei Zeng, Huichao Li, Shuo Liu, Lei Yang, Changfa Xia, Rongshou Zheng, Fei Ma, Lifang Liu, Ning Wang, Lixue Xuan, Wanqing Chen
BACKGROUND: Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China. To estimate the survival differences among patients with different stages and various subtypes of breast cancer, we conducted a hospital-based multi-center study on breast cancer in Beijing, China. METHODS: All resident patients diagnosed with primary, invasive breast cancer between January 1, 2006 and December 31, 2010 from four selected hospitals in Beijing were included and followed up until December 31, 2015...
October 25, 2017: Chinese Journal of Cancer
Lei Liu, Yayun Chi, Jiajian Chen, Jingyan Xue, Linlin Deng, Naisi Huang, Jianghua Shao, Jiong Wu
Luminal breast cancers (BC) account for majority of breast cancer. Due to its heterogeneity and the development of treatment resistance, luminal BC patients can vary substantially. Long noncoding RNAs (lncRNAs), as we known, is involved in breast cancer progression. Here, we aim to identify the lncRNAs which are involved in the particular type luminal BC progression. By Gene Chips analysis, we found a novel lncRNA00544, which was highly expressed in the metastatic axillary nodes compared with corresponding luminal BC tissues (fold change = 2...
September 28, 2017: Scientific Reports
Jingming Ye, Wenjun Wang, Ling Xu, Xuening Duan, Yuanjia Cheng, Ling Xin, Hong Zhang, Shuang Zhang, Ting Li, Yinhua Liu
OBJECTIVE: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for luminal A breast cancer. METHODS: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival (DFS), overall survival (OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups...
August 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Yuru Bai, Lu Qiao, Ning Xie, Yongquan Shi, Na Liu, Jinhai Wang
BACKGROUND: Despite advances in early diagnosis and treatment, cancer remains the major cause of mortality in the world. The Tob/BTG antiproliferative (APRO) protein family is reported to participate in diverse human diseases. However, there's little known about their expression and prognostic values in most human cancers. METHODS: We performed a detailed cancer vs. normal analysis. The mRNA expression levels of APRO family in various cancers were analyzed via the Oncomine database...
2017: PloS One
Ning Liu, Zhigang Yang, Xiaozhen Liu, Yun Niu
BACKGROUND AND OBJECTIVES: To investigate the association between different molecular subtype (MST) and the axillary lymph nodal (ALN) status. MATERIALS AND METHODS: A total of 528 female patients with primary breast cancer were collected. Survival estimates were calculated using the Kaplan-Meier method, univariate and multivariate logistic regression models. RESULTS: Triple negative and Luminal A breast cancers were more frequently node-negative (N0) when compared to Luminal B and Her-2 positive cancers (77...
August 15, 2017: Oncotarget
Bigang Liu, Shuai Gong, Qiuhui Li, Xin Chen, John Moore, Mahipal V Suraneni, Mark D Badeaux, Collene R Jeter, Jianjun Shen, Rashid Mehmood, Qingxia Fan, Dean G Tang
This project was undertaken to address a critical cancer biology question: Is overexpression of the pluripotency molecule Nanog sufficient to initiate tumor development in a somatic tissue? Nanog1 is critical for the self-renewal and pluripotency of ES cells, and its retrotransposed homolog, NanogP8 is preferentially expressed in somatic cancer cells. Our work has shown that shRNA-mediated knockdown of NanogP8 in prostate, breast, and colon cancer cells inhibits tumor regeneration whereas inducible overexpression of NanogP8 promotes cancer stem cell phenotypes and properties...
August 8, 2017: Oncotarget
Xi-Long Zhao, Yong Lin, Jun Jiang, Zhuo Tang, Shuai Yang, Lu Lu, Yan Liang, Xue Liu, Jiao Tan, Xu-Gang Hu, Qin Niu, Wen-Juan Fu, Ze-Xuan Yan, De-Yu Guo, Yi-Fang Ping, Ji Ming Wang, Xia Zhang, Hsiang-Fu Kung, Xiu-Wu Bian, Xiao-Hong Yao
Cancer stem cells/cancer-initiating cells (CICs) and their microenvironmental niche play a vital role in malignant tumour recurrence and metastasis. Cancer-associated fibroblasts (CAFs) are major components of the niche of breast cancer-initiating cells (BCICs), and their interactions may profoundly affect breast cancer progression. Autophagy has been considered to be a critical process for CIC maintenance, but whether it is involved in the cross-talk between CAFs and CICs to affect tumourigenesis and pathological significance has not been determined...
November 2017: Journal of Pathology
Yao Chen, Ling Wang, Hao Liu, Fahuan Song, Caiyun Xu, Kai Zhang, Qing Chen, Shuang Wu, Yunqi Zhu, Ying Dong, Min Zhou, Hong Zhang, Mei Tian
PURPOSE: The aim of the study was to non-invasively evaluate the anticancer activity of a traditional Chinese medicine-Huaier, combined with paclitaxel (PTX) in breast cancer bearing mice by detecting dynamic metabolic changes with positron emission tomography (PET). PROCEDURES: Balb/c nude mice were randomly divided into one of the four groups: Huaier, PTX, PTX + Huaier, or the control. PET imaging with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) was performed to monitor the metabolic changes in BT474 (luminal B) and MDA-MB-231 (triple-negative) breast cancer xenografts...
August 9, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"